patient dose News
-
First Patients Dosed in Trial of Pharmaxis Scar Reduction Drug
Collaboration with research team led by Professor Fiona Wood AM doses first patients in trial of 50 patients with established scars 3-month placebo-controlled study to report safety and tolerability endpoints as well as measures of scar structure and appearance in 2H 2022 PXS-6302 is a first in class topical inhibitor of the lysyl oxidase enzymes that are involved in formation and maintenance ...
-
Update on Biosceptre’s Phase 1 Clinical Trial for First-in-Class Oncology Vaccine BIL06v
Biosceptres’ Phase I clinical trial for peptide vaccine BIL06v has now completed enrolment of the first cohort of ten patients at the first dose, and all enrolled patients have received treatment. The trial was initiated in August and, subject to a scheduled safety review this week, it is expected that recruitment of the second cohort will begin before end of November. ...
-
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis. London, 11 February 2020 - This significant milestone sees a best in class, novel multi-target drug developed ...
By Benevolent
-
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2021, and provided a business update. “After a busy 2021 with new patients dosed across three clinical trials, we acted in early January to strategically position AVROBIO ...
-
Regor announces the first patient dosed in the U.S. in the Phase II clinical trial for RGT-075, a novel small molecule GLP-1R agonist
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase II clinical trial of the Company’s novel oral small molecule GLP-1 receptor agonist RGT-075 in the U.S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a well-characterized class of hypoglycemic ...
-
First patient dosed in SCIB1 Phase 2 clinical trial
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the enrolment and treatment of the first patient in its multicentre SCIB1 Phase 2 clinical trial at the Churchill Hospital, Oxford University Hospitals Trust, UK. The Phase 2 study is designed to assess whether the addition of SCIB1 to pembrolizumab ...
By Scancell
-
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
Clinical proof-of-concept achieved based on positive data from the first two patients dosed at half the target dose of cells in Part A of Phase 1/2 study First patient achieved insulin independence at Day 270; positive data in second patient; third patient has received full target dose with initiation of Part B VX-880 generally well tolerated in all three patients dosed to date ...
-
Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Tel Aviv, ...
-
Cellphire Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Thrombosomes in Bleeding Thrombocytopenic Patients
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that the first patient has been dosed in the company’s Phase 2 dose-ranging study of Thrombosomes®, a platelet-based freeze-dried hemostatic agent, in bleeding patients with thrombocytopenia. The ...
-
Valo Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy
Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that dosing has commenced in its Phase 2 study — a multi-center ...
-
Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“the Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the first patient was dosed in the KEYNOTE-B79 Phase 1b trial (NCT04991948). The KEYNOTE-B79 trial is part of a collaboration with MSD, a tradename of Merck ...
-
Regor announces the first patient dosed in the U.S. in the Phase I clinical trial for RGT-419B, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase I clinical trial of the Company’s next generation targeted inhibitor RGT-419B for the treatment of breast cancer. RGT-419B is a new generation CDK2/4/6, small molecule inhibitor with an optimized kinase ...
-
Showcase
RTsafe’s core role for the development of German guidelines for a standard, safe and efficient implementation of Single-Isocentric Multi-Focal SRS throughout the country
RTsafe is happy to announce that its PRIME and Pseudopatient 3D phantoms, have been selected by a consortium of high-end German Radiotherapy Institutions – led by the Division of Medical Physics of the Department of Radiation Oncology at the Medical Center of University of Freiburg – towards supporting a study whose results will be used for the development of national guidelines in ...
By RTsafe
-
Artugen Therapeutics Announces First Patient Dosed with ART24, Artugen`s first clinical product candidate for prevention of recurrence of Clostridium difficile infection
ART24 granted Fast Track Designation First Patient Dosed Concord, Mass., and Dublin, Ireland March 12, 2020 — Artugen Therapeutics Limited, a Company developing novel live biotherapeutics (LBPs) for patients living with infectious, inflammatory and oncologic diseases announced today the first patient dosed with ART24, the Company’s first clinical product candidate for prevention ...
-
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients In the first two dose cohorts, all four patients exhibited above normal α-Gal A activity, ranging from 3-fold to 15-fold above mean normal; patients in the first dose cohort have maintained elevated activity for one year and are now in the long-term ...
-
Aurealis Therapeutics Diabetic Foot Ulcer Dose Escalation Patient Trial Low Therapeutic Dose Cohort Completed Successfully, Advances to Medium Therapeutic Dose Group
Aurealis Therapeutics, a biopharmaceutical company developing its groundbreaking four-in-one technology -based product AUP-16, announced today that it has successfully completed the low therapeutic dose cohort in the diabetic foot ulcer (DFU) patient trial and has already enrolled and dosed the first patients in the medium therapeutic dose cohort. The primary endpoint of this dose escalation ...
-
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology ...
-
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American ...
-
Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder
Camurus (NASDAQ STO: CAMX) today announces that the company’s license partner Rhythm Pharmaceuticals has dosed the first patients in a Phase 3 trial evaluating weekly setmelanotide subcutaneous depot in patients six years of age and older with a rare genetic disease of obesity. “We are pleased with the progress of our collaboration with Rhythm and today’s announcement of the ...
By Camurus AB
-
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Preliminary data showed that isaralgagene civaparvovec, or ST-920, was generally well tolerated All four patients in the first two dose cohorts exhibited above normal α-Gal A activity, which was maintained for up to one year for the first patient treated Based on these data, Sangamo has initiated Phase 3 planning The fifth patient was recently dosed, in the third dose cohort Q3 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you